The Directors: Ray DuBois and Roy Jensen on how COE guides cancer care in rural America
“We’re just going to have to ride through this and not give up.”

Regulatory News

Backlog of work grows at NIH as staff members are being hounded to quit

Guest Editorial

Rathmell: My mentor recognized a cliff I was going to fall off before I did.
“He was there to stand with me while I fell, and then made me look up and see that I needed to lean into the experience.”

Guest Editorial

In support of three coordinated CCSG components reducing our national burden of cancer

Guest Editorial

New drugs don’t appear out of thin air

In Brief

W. Kimryn Rathmell awarded the ACS 2025 Medal of Honor

AACR names 2025 fellows of AACR Academy, AACR Academy president

Kathy Giusti joins Thyme Care as strategic advisor for patient experience

Tari King appointed chief surgical officer for cancer service line, co-director of Glenn Family Breast Center at Winship, chief of Division of Breast Surgery at Emory

Matteo Paz wins 2025 Regeneron Science Talent Search

Jeffrey Rathmell named chair of the UChicago Ben May Department for Cancer Research, director of Ludwig Center for Metastasis Research

Drugs & Targets

EC approves Opdivo + Yervoy as first-line treatment for HCC

China’s National Medical Products Administration grants Breakthrough Therapy designation to olverembatinib for Ph+ ALL

FDA grants Orphan Drug designation to rhenium obisbemeda for leptomeningeal metastases in lung cancer

FDA approves Tevimbra + chemo for advanced ESCC

University of New England licenses cancer biomarker test to Satya Diagnostics

FDA accepts review for odronextamab BLA in r/r follicular lymphoma

In The Clinic

Survey reveals most Americans are uninformed about HPV
A vaccine can prevent cancer—most people don’t take it

Free Trials & Tribulations

The new therapeutic imperative in cancer management: Sequence, biosimulate, treat

Trials & Tribulations

LLS former CSO: Immunotherapy, precision medicine redefined blood cancer treatment

Trials & Tribulations

Physicians and biopharma should improve accessibility of cancer trials

Trials & Tribulations

From clinician scientist to nonprofit CEO

Latest Issue

Read the latest issue

DOWNLOAD THE PDF

NEWS ALERTS

Stay up to date on the latest news in oncology by joining our mailing list.

UPCOMING EVENTS

Mar 2025

NCCN 2025 Annual Conference

Apr 2025

Miami Leukemia Symposium

Cellicon Valley ’25: The Future of Cell and Gene Therapies

May 2025

NCCN Oncology Policy Summit: Primary Care and Oncology Collaboration to Improve Patient Outcomes

2025 AAADV Workshop

View All Events

Conversations with The Cancer Letter

Shearwood McClelland III: “When you stand for something, you’re always going to be attacked.”

Brian Rivers: Celebrating Black history reinforces the dynamic culture of America
“It gives America, in part, its identity.”

RWD company documents baseline trends in women’s cancers before Trump’s policy changes

After 25 years as FDA’s chief cancer strategist, Richard Pazdur reflects on opportunities for change at the agency

Contributors

Guido Marcucci, MD

Accelerating translational research in leukemia: The City of Hope approach

W. Kimryn Rathmell, MD, PhD, MMHC

Raising awareness—for everyone

Yuman Fong, MD

Harnessing innovation: The next frontier in surgical oncology

W. Kimryn Rathmell, MD, PhD, MMHC

Telling our stories: Bidirectional benefits of sharing our history

Trending Stories

In the Headlines: What are Jay Bhattacharya’s plans for NIH?
Backlog of work grows at NIH as staff members are being hounded to quit
Trump et al. focus on NIH, cancer—and how peer review is done
Bhattacharya provides calm answers to anxious questions at confirmation hearing
Trump nominee for NIH director calls for transparency, audits of indirect costs
Rathmell: My mentor recognized a cliff I was going to fall off before I did.
“He was there to stand with me while I fell, and then made me look up and see that I needed to lean into the experience.”
The new therapeutic imperative in cancer management: Sequence, biosimulate, treat

Recent Issues

The Cancer Letter is an independent weekly news publication and the leading source for information on the issues that shape oncology.

The Directors: Ray DuBois and Roy Jensen on how COE guides cancer care in rural America
“We’re just going to have to ride through this and not give up.”

Backlog of work grows at NIH as staff members are being hounded to quit

Rathmell: My mentor recognized a cliff I was going to fall off before I did.
“He was there to stand with me while I fell, and then made me look up and see that I needed to lean into the experience.”

In support of three coordinated CCSG components reducing our national burden of cancer

New drugs don’t appear out of thin air

W. Kimryn Rathmell awarded the ACS 2025 Medal of Honor

AACR names 2025 fellows of AACR Academy, AACR Academy president

Kathy Giusti joins Thyme Care as strategic advisor for patient experience

Tari King appointed chief surgical officer for cancer service line, co-director of Glenn Family Breast Center at Winship, chief of Division of Breast Surgery at Emory

Matteo Paz wins 2025 Regeneron Science Talent Search

Jeffrey Rathmell named chair of the UChicago Ben May Department for Cancer Research, director of Ludwig Center for Metastasis Research

EC approves Opdivo + Yervoy as first-line treatment for HCC

China’s National Medical Products Administration grants Breakthrough Therapy designation to olverembatinib for Ph+ ALL

FDA grants Orphan Drug designation to rhenium obisbemeda for leptomeningeal metastases in lung cancer

FDA approves Tevimbra + chemo for advanced ESCC

University of New England licenses cancer biomarker test to Satya Diagnostics

FDA accepts review for odronextamab BLA in r/r follicular lymphoma

Survey reveals most Americans are uninformed about HPV
A vaccine can prevent cancer—most people don’t take it

The new therapeutic imperative in cancer management: Sequence, biosimulate, treat

LLS former CSO: Immunotherapy, precision medicine redefined blood cancer treatment

Physicians and biopharma should improve accessibility of cancer trials

From clinician scientist to nonprofit CEO

Shearwood McClelland III: “When you stand for something, you’re always going to be attacked.”

Brian Rivers: Celebrating Black history reinforces the dynamic culture of America
“It gives America, in part, its identity.”

RWD company documents baseline trends in women’s cancers before Trump’s policy changes

After 25 years as FDA’s chief cancer strategist, Richard Pazdur reflects on opportunities for change at the agency

Guido Marcucci, MD

W. Kimryn Rathmell, MD, PhD, MMHC

Yuman Fong, MD

W. Kimryn Rathmell, MD, PhD, MMHC

Never miss an issue!

Login

The Directors: Ray DuBois and Roy Jensen on how COE guides cancer care in rural America“We’re just going to have to ride through this and not give up.”

Shearwood McClelland III: “When you stand for something, you’re always going to be attacked.”

Brian Rivers: Celebrating Black history reinforces the dynamic culture of America“It gives America, in part, its identity.”

RWD company documents baseline trends in women’s cancers before Trump’s policy changes

After 25 years as FDA’s chief cancer strategist, Richard Pazdur reflects on opportunities for change at the agency

Never miss an issue!

Login

The Directors: Ray DuBois and Roy Jensen on how COE guides cancer care in rural America
“We’re just going to have to ride through this and not give up.”

Brian Rivers: Celebrating Black history reinforces the dynamic culture of America
“It gives America, in part, its identity.”